- Home
- MSGS vs IONS Comparison
MSGS vs IONS Comparison
Compare MSGS & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSGS
- IONS
- Stock Information
- Founded
- MSGS 1879
- IONS 1989
- Country
- MSGS United States
- IONS United States
- Employees
- MSGS N/A
- IONS N/A
- Industry
- MSGS Services-Misc. Amusement & Recreation
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- MSGS Consumer Discretionary
- IONS Health Care
- Exchange
- MSGS Nasdaq
- IONS Nasdaq
- Market Cap
- MSGS 5.2B
- IONS 6.0B
- IPO Year
- MSGS N/A
- IONS 1991
- Fundamental
- Price
- MSGS $219.53
- IONS $32.68
- Analyst Decision
- MSGS Buy
- IONS Buy
- Analyst Count
- MSGS 1
- IONS 18
- Target Price
- MSGS $240.00
- IONS $62.00
- AVG Volume (30 Days)
- MSGS 85.3K
- IONS 1.5M
- Earning Date
- MSGS 02-04-2025
- IONS 02-19-2025
- Dividend Yield
- MSGS N/A
- IONS N/A
- EPS Growth
- MSGS 57.82
- IONS N/A
- EPS
- MSGS 2.91
- IONS N/A
- Revenue
- MSGS $1,037,410,000.00
- IONS $803,067,000.00
- Revenue This Year
- MSGS N/A
- IONS N/A
- Revenue Next Year
- MSGS $8.60
- IONS $10.85
- P/E Ratio
- MSGS $75.25
- IONS N/A
- Revenue Growth
- MSGS 14.45
- IONS 30.57
- 52 Week Low
- MSGS $178.35
- IONS $31.40
- 52 Week High
- MSGS $237.99
- IONS $52.49
- Technical
- Relative Strength Index (RSI)
- MSGS 48.00
- IONS 40.58
- Support Level
- MSGS $214.77
- IONS $31.40
- Resistance Level
- MSGS $219.57
- IONS $35.37
- Average True Range (ATR)
- MSGS 4.34
- IONS 1.31
- MACD
- MSGS -0.07
- IONS -0.23
- Stochastic Oscillator
- MSGS 49.30
- IONS 29.09
About MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.